Vitrolife AB (publ) (STO:VITR) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Investors in Vitrolife AB (publ) (STO:VITR) had a good week, as its shares rose 6.6% to close at kr151 following the release of its third-quarter results. It was a credible result overall, with revenues of kr835m and statutory earnings per share of kr3.78 both in line with analyst estimates, showing that Vitrolife is executing in line with expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

After the latest results, the four analysts covering Vitrolife are now predicting revenues of kr3.72b in 2026. If met, this would reflect a satisfactory 6.0% improvement in revenue compared to the last 12 months. Per-share earnings are expected to bounce 37% to kr4.45. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr3.72b and earnings per share (EPS) of kr4.44 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

View our latest analysis for Vitrolife

The analysts reconfirmed their price target of kr194, showing that the business is executing well and in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Vitrolife analyst has a price target of kr230 per share, while the most pessimistic values it at kr160. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that Vitrolife's revenue growth is expected to slow, with the forecast 4.8% annualised growth rate until the end of 2026 being well below the historical 20% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 15% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Vitrolife.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Vitrolife's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Vitrolife analysts - going out to 2027, and you can see them free on our platform here.

It might also be worth considering whether Vitrolife's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.